Oligodendroglioma, IDH-mutant and 1p/19q-codeleted

Clinical trials for Oligodendroglioma, IDH-mutant and 1p/19q-codeleted explained in plain language.

Never miss a new study

Get alerted when new Oligodendroglioma, IDH-mutant and 1p/19q-codeleted trials appear

Sign up with your email to follow new studies for Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1 Not yet recruiting 1 Completed 1

New hope for brain tumor patients: targeted drug shows promise in phase 3 trial

Disease control Recruiting now

This study tests a drug called safusidenib in people with a type of brain tumor (glioma) that has a specific gene mutation (IDH1). The trial has three parts: one for recurrent tumors, one for high-risk tumors after standard treatment, and one for a specific tumor type after surge…

Matched conditions: OLIGODENDROGLIOMA, IDH-MUTANT AND 1P/19Q-CODELETED

Phase 3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control

Last updated Aug 30, 2026 00:00 UTC

Oligodendroglioma, IDH-mutant and 1p/19q-codeleted

Get alerted when new Oligodendroglioma, IDH-mutant and 1p/19q-codeleted trials appear

New hope for brain tumor patients: targeted drug shows promise in phase 3 trial